Medically Integrated Pharmacy Quality Initiatives in Large Multi-Site Oncology Networks

Gury Doshi, M.D. Medical Director, Oral Oncolytics Texas Oncology

the property of the autho

permission required for reuse

ASCO[®] Quality

Care Symposium

PRESENTED AT








More breakthroughs. More victories."

- 460 Physicians
- 210 Locations
- 42 Pharmacy locations
- 1 Central Pharmacy





PRESENTED AT:

Does your practice have an in-house pharmacy/dispensary that dispenses oral oncolytics?

A. YESB. NO





#ASCOQLTY19 Slides are the property of the author, permission required for reuse.

Agree/Disagree:

A Medically Integrated Pharmacy leads to improved patient care compared to other (specialty) pharmacy.





#ASCOQLTY19 Slides are the property of the author, permission required for reuse.

Objective: Define Medically Integrated Pharmacy Care (MIPC) Benefits of MIPC



Increase access to therapy decrease financial burden Coordinated care by their medical team



Improved management/care of your patient "<u>No one</u> cares for your patients like you do."



Control/delivery of high quality oncology care in a value based world



Oral Oncology Drugs as Cancer Therapy

25-35% of all new cancer drugs *in development* are oral drugs₁

2009

2019

Of 22 new drug approvals to date,

7 drug approvals are ORAL hematology/oncology drugs

1. Mosely W, et al. Community Oncology 2009;6:358-61

www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019



Oral Oncolytics a New Paradigm to Quality Patient Care

Oral cancer medicines impact several aspects of cancer treatment

Drug accessibility

ASCO Quality

Care Symposium

Financial burden

Shifting traditional provider roles and responsibilities to patients & caregivers


Safety monitoring

Adherence concerns




Medically Integrated Pharmacy- Value

TRUE Integration of Pharmacy/Medical Care




Integration of Medical & Pharmacy Care





Prior Authorization Details



PA DETAILS

Appeal denials: PAP requirement, off label

RX Resolve: Formulary change, Therapy Change, Out of network, No PA needed Denials: Off label, step therapy

Texas Oncology RX PA_PAS Data



#ASCOQLTY19 Slides are the property of the author, permission required for reuse.

PA team secures prior authorizations, appeals and resolves dispensing issues:

- Identifies formulary preference
- Identifies in network pharmacies
- Assists high dollar reviews and quantity limits
- Educate or conference dispensing pharmacy with the PBM or plan for claims processing
- Proactively communicate formulary changes
- Communicates insurance updates with clinic
- Turn around time 10 min to 48 hrs
- Proactively works PAs prior to expiration
- Immediate referral to financial assistance
- Developed relationship with other Specialty Pharmacy to track patient's prescription
- Relationship with pharmacy, physician, patient, insurance

Financial Burden Limits Access

VOLUME 36 · NUMBER 5 · FEBRUARY 10, 2018

JOURNAL OF CLINICAL ONCOLOGY

ORIGINAL REPORT

Association of Patient Out-of-Pocket Costs With Prescription Abandonment and Delay in Fills of Novel Oral

Anticancer Agents

Jalpa A. Doshi, Pengxiang Li, Hairong Huo, Amy R. Pettit, and Katrina A. Armstrong

Author affiliations and support information (if applicable) appear at the end of this article. Published at jco.org on December 20, 2017. Corresponding author: Jalna A. Doshi

A B S T R A C T

Purpose The number of novel oral anticancer agents is increasing, but financial barriers may limit access. We examined associations between out-of-pocket (OOP) costs and reduced and/or delayed treatment initiation


- 38,111 scripts
- 18% overall abandonment rate
- Relationship between OOP cost with delayed/reduced treatment initiation

Abandonment Rate	OOP cost \$
10%	< \$ 10
13.5%	50-100
31.7%	100-500
41%	500-2000
49.4 %	> 2000



Patient Assistance Details

PAS Total Value in \$K



- Savings Cards process as primary to include Vouchers, Free Trial Offers and Co-Pay Cards
- Foundation grants process as secondary
- PAP includes Bridge programs and 1st fill
 - Drug ships to patient home
 - Few programs issue pharmacy processing cards

Swift transition from PA to PAS for comprehensive financial screening

Texas Oncology RX PA_PAS Data



#ASCOQLTY19 Slides are the property of the author permission required for reuse.

Medically Integrated Pharmacy Difference

	MIPC	Other pharmacy
Time to obtain medication	24-48 hours	Days- weeks
Prior authorization	hours/performed by MIPC team	Hrs-days, multiple people/steps
Patient assistance	Provided by oncology MIPC team	Patient burden
Concurrent medication check	Accurate/same EMR	Not possible
Adverse effects	Evaluated and managed	N/A
Care delivery	Coordinated/optimal	Fragmented



#ASCOQLTY19 Slides are the property of the author, permission required for reuse.

Patient & Team Feedback

- "Convenience in receiving medication"
- "Time to receiving medication"
- "Interaction with staff"
- "General satisfaction with the care provided"



• "You sure are there for us and we appreciate you so much. It's been such a stressful day this is the first glimmer of hope all day long."

Texas Oncology Patient



#ASCOQLTY19 Slides are the property of the author, permission required for reuse.

PRESENTED BY:

Conclusion: Benefit of MIPC



Integrated total care plan by the medical team Improved patient satisfaction & outcomes



coordinated management/care of your patient "<u>No one</u> cares for your patients like you do."



Control/delivery of high quality oncology care for patients in a value based world



#ASCOQLTY19 Slides are the property of the autho permission required for reuse.

Agree/Disagree:

A Medically Integrated Pharmacy leads to improved patient care compared to other (specialty) pharmacy.






#ASCOQLTY19 Slides are the property of the author, permission required for reuse.

Comparison Responses to Slide #16 and #4

Current Results



A 0%
B 33%
C 67%

Previous Results



#ASCOQLTY19 Slides are the property of the author, permission required for reuse.

Future Direction

- AE monitoring:
 - Patient education, Utilizing technology solutions to enhance AE monitoring, early interventions
- Value Based Care: avoid ER visits, decrease hospitalization
- Adherence: what matters, demonstrating value to payers
- DIR fees
- Decrease costs: starter 14 day/partial fills



• Patient-Centered Standards for Medically Integrated Dispensing: ASCO/NCODA Standards



#ASCOQLTY19 Slides are the property of the author, permission required for reuse.

Thanks to ... Texas Oncology Teams



More breakthroughs. More victories."

PA/PAS Team: Margaret Harville, Supervisor Shannon Ford Gracie Gonzalez Michelle Koonce Kathleen Lucquete Lindsey Robertson **Denise Serrano** Sabrina Taylor Kasey Thiele Nicole Zamora

Pharmacy Team: Jim Schwartz, Executive Director Neal Dave Mark Lawson Chris Sellers **Brandon Alexander** Kareem Coleman Lois Miles



ASCO[®] Quality

Care Symposium